These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Targeted therapies to improve CFTR function in cystic fibrosis. Brodlie M; Haq IJ; Roberts K; Elborn JS Genome Med; 2015 Sep; 7():101. PubMed ID: 26403534 [TBL] [Abstract][Full Text] [Related]
23. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
24. Promising new era dawns for cystic fibrosis treatment. Corbyn Z Lancet; 2012 Apr; 379(9825):1475-6. PubMed ID: 22530244 [No Abstract] [Full Text] [Related]
25. Ivacaftor in a G551D homozygote with cystic fibrosis. Harrison MJ; Murphy DM; Plant BJ N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763 [No Abstract] [Full Text] [Related]
26. [New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein]. Hubert D; Bui S; Marguet C; Colomb-Jung V; Murris-Espin M; Corvol H; Munck A Rev Mal Respir; 2016 Oct; 33(8):658-665. PubMed ID: 26806675 [TBL] [Abstract][Full Text] [Related]
27. A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Southern KW; Patel S; Sinha IP; Nevitt SJ Paediatr Respir Rev; 2019 Apr; 30():25-26. PubMed ID: 31128877 [No Abstract] [Full Text] [Related]
28. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor. Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905 [No Abstract] [Full Text] [Related]
30. Excitement mounts for first disease-modifying cystic fibrosis drugs. Opar A Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393 [No Abstract] [Full Text] [Related]
31. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation. Bulloch MN; Hanna C; Giovane R Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346 [TBL] [Abstract][Full Text] [Related]
32. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
33. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis. O'Reilly R; Elphick HE Drug Des Devel Ther; 2013; 7():929-37. PubMed ID: 24039402 [TBL] [Abstract][Full Text] [Related]
34. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis. Mayer-Hamblett N; Boyle M; VanDevanter D Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594 [TBL] [Abstract][Full Text] [Related]
35. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM; N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693 [TBL] [Abstract][Full Text] [Related]
36. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL; N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692 [TBL] [Abstract][Full Text] [Related]
37. Ivacaftor CFTR Potentiator Therapy is Efficient for Pancreatic Manifestations in Cystic Fibrosis. Kounis I; Lévy P; Rebours V Am J Gastroenterol; 2018 Jul; 113(7):1058-1059. PubMed ID: 29887601 [No Abstract] [Full Text] [Related]
39. Cystic fibrosis in the era of genomic medicine. Milla CE Curr Opin Pediatr; 2013 Jun; 25(3):323-8. PubMed ID: 23652683 [TBL] [Abstract][Full Text] [Related]
40. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis. Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]